Article

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1

2023-05-04

Abstract excerpt

The increasing prevalence of the highly antibody-evasive Omicron sublineages increases the risk of breakthrough infections and leaves high-risk and vulnerable immunocompromised individuals with no effective options for prophylactic or therapeutic antibody treatments. Here, we report a heavily mutated anti-RBD monoclonal antibody, Acovimab, directed against a site in the receptor-binding motif (RBM) region of the C...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 76692ccb-3476-5897-9559-b37e1d982ff7
DOI: 10.1101/2023.05.04.539267

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1DOI 10.1101/2023.05.04.539267Read

Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.Semantic proximity Read

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBBSemantic proximity Read

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity Read

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activitySemantic proximity Read

Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concernSemantic proximity Read

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsSemantic proximity Read

19n01, a Broadly Neutralizing Antibody Against Omicron BA.1, BA.2, BA.4/5, and Other SARS-CoV-2 Variants of ConcernSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesSemantic proximity Read

A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 VariantSemantic proximity Read

SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasionSemantic proximity Read